Alvimopan - CAS 156053-89-3
Catalog number:
156053-89-3
Category:
Inhibitor
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
C25H32N2O4
Molecular Weight:
424.53
COA:
Inquire
Targets:
Opioid Receptor
Description:
Alvimopan is a novel, oral, peripherally acting antagonist of the mu opioid receptor, which can help gastrointestinal recovery after surgery. Phase III IC50: Mu-type opioid receptor= 1.7 nM
Publictions citing BOC Sciences Products
  • >> More
Purity:
≥98%
Appearance:
Solid powder
Synonyms:
2-[[(2S)-2-benzyl-3-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethylpiperidin-1-yl]propanoyl]amino]acetic acid ADL 8-2698 ADL8-2698 alvimopan alvimopan anhydrous anhydrous alvimopan Entereg LY 246736 LY-246736 LY246736 trans-3,4-dimethyl-4-(3-hydroxyphenyl) pipe
Solubility:
Soluble in DMSO
Storage:
Store in a cool and dry place and at 0 - 4℃ for short term (days to weeks) or -83℃ for long term (months to years).
MSDS:
Inquire
Application:
A peripheral μ-opioid receptor antagonist. Gastroprokinetic.
Shelf Life:
2 years
Quantity:
Grams-Kilos
Boiling Point:
684.1±55.0 °C | Condition: Press: 760 Torr
Density:
1.166±0.06 g/cm3
InChIKey:
UPNUIXSCZBYVBB-JVFUWBCBSA-N
InChI:
1S/C25H32N2O4/c1-18-16-27(12-11-25(18,2)21-9-6-10-22(28)14-21)17-20(24(31)26-15-23(29)30)13-19-7-4-3-5-8-19/h3-10,14,18,20,28H,11-13,15-17H2,1-2H3,(H,26,31)(H,29,30)/t18-,20-,25+/m0/s1
Canonical SMILES:
CC1CN(CCC1(C)C2=CC(=CC=C2)O)CC(CC3=CC=CC=C3)C(=O)NCC(=O)O
Current Developer:
Adolor Corporation; Cubist Pharmaceuticals
1.Are we doing "better"? The discrepancy between perception and practice of enhanced recovery after cystectomy principles among urologic oncologists.
Baack Kukreja JE1, Messing EM2, Shah JB3. Urol Oncol. 2016 Mar;34(3):120.e17-21. doi: 10.1016/j.urolonc.2015.10.002. Epub 2015 Nov 14.
PURPOSE: The concept of enhanced recovery after surgery has been around since the 1990s when it was first introduced as a means to improve postoperative recovery of general surgical patients. In the field of urology, the uptake of enhanced recovery pathways has been slow for unclear reasons. Recently, interest in enhanced recovery after cystectomy (ERAC) has been increasing, but the current urologic oncology practice patterns remain unclear. In this study, we investigate modern perioperative patterns of care and rates of application of ERAC principles by cystectomy surgeons.
2.New Options in Constipation Management.
Davis M1,2,3, Gamier P4,5,6. Curr Oncol Rep. 2015 Dec;17(12):55. doi: 10.1007/s11912-015-0481-x.
Constipation is common in the general population and for those on opioids and/or who are suffering from advanced cancer. Self-management consists of dietary changes, exercise, and laxatives. However, responses to self-management efforts are often inadequate to relieve the subjective and objective experience of constipation. Multiple new anti-constipating medications have recently been tested in randomized trials and the following are available commercially: probiotics, prucalopride, lubiprostone, linaclotide, elobixibat, antidepressants, methylnaltrexone, alvimopan, and naloxegol. This review will discuss the evidence-based benefits of these medications and outline an approach to managing constipation.
3.Pharmacological management to prevent ileus in major abdominal surgery: a systematic review and meta-analysis.
Drake TM1,2, Ward AE3. J Gastrointest Surg. 2016 Apr 12. [Epub ahead of print]
BACKGROUND: Prolonged ileus is a common complication following gastrointestinal surgery, with an incidence of up to 40 %. Investigations examining pharmacological treatment of ileus have proved largely disappointing; however, recently, several compounds have been shown to have benefited when used as prophylaxis to prevent ileus.
4.Constipation: opioid antagonists in people prescribed opioids.
Ahmedzai SH1, Boland JW. BMJ Clin Evid. 2015 Sep 11;2015. pii: 2407.
INTRODUCTION: Constipation is a common adverse effect of opioids. As an example, constipation is reported in 52% of people with advanced malignancy, and this figure rises to 87% in people who are terminally ill and taking opioids. There is no reason to believe that people with chronic non-malignant disease who are prescribed opioids will be any less troubled by this adverse effect.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Opioid Receptor Products


CAS 77614-16-5 Dermorphin

Dermorphin
(CAS: 77614-16-5)

Dermorphin, a naturally occurring heptapeptide originally found in the skin of amphibians, is a μ-opioid receptor(MOR) agonist with analgesic and antinociceptiv...

CAS 152-02-3 Levallorphan

Levallorphan
(CAS: 152-02-3)

Levallorphan, an allylmorphinan derivative, has been found to be a μ-opioid receptor antagonist that could be an analgesic agent as an prescription drug.

CAS 170713-75-4 Nociceptin

Nociceptin
(CAS: 170713-75-4)

Nociceptin, a 17 amino acid neuropeptide involved in a variety of biological systems, is the endogenous ligand of the nociceptin receptor, acting as a potent an...

Alvimopan monohydrate
(CAS: 1383577-62-5)

The monohydrate salt form of Alvimopan could be commonly used in postoperative recovery of gastrointestinal for acting as a mu-opioid receptor (PAM-OR) antagoni...

CAS 59263-76-2 Meptazinol Hydrochloride

Meptazinol Hydrochloride
(CAS: 59263-76-2)

Meptazinol is a unique centrally active opioid analgesic, which inhibits [3H]-dihydromorphine binding with IC50 of 58 nM.

Lexanopadol
(CAS: 1357348-09-4)

Lexanopadol is a potent Opioid mu receptor agonist originated by Grunenthal. Lexanopadol is suited for the management of moderate to severe chronic pain, includ...

TRV130 Racemate
(CAS: 1401028-25-8)

The racemate form of TRV130 which is an oxaspiro compound that has been found to be a μ-opioid receptor G protein ligand and could be used in pain therapy.

CAS 357-08-4 Naloxone hydrochloride

Naloxone hydrochloride
(CAS: 357-08-4)

Naloxone HCl is an opioid inverse agonist drug used to counter the effects of opiate overdose.

CAS 1108147-88-1 MCOPPB triHydrochloride

MCOPPB triHydrochloride
(CAS: 1108147-88-1)

The trihydrochloride salt form of MCOPPB, an effective full agonist of nociceptin receptor, could be a good antianxiety agent with few side-effects. pKi: 10.07.

CP866087
(CAS: 519052-02-9)

CP866087 is a selective mu-opioid receptor antagonist.

(+)-Igmesine hydrochloride
(CAS: 130152-35-1)

Igmesine is a selective σ1 receptor ligand (KD = 19.1 nM), with nearly no activity at σ2 receptors (IC50 > 1000 nM). It was developed by Pfizer. Igmesine inhibi...

CAS 244218-51-7 JTC-801

JTC-801
(CAS: 244218-51-7)

JTC-801 is a selective opioid receptor-like1 (ORL1) receptor antagonist with IC50 of 94 nM, weakly inhibits receptors δ, κ, and μ. It is an opioid analgesic dru...

Nalfurafine hydrochloride
(CAS: 152658-17-8)

Nalfurafine is a selective and centrally-penetrant κ-opioid receptor (KOR) agonist without significant activity on μ- and δ-opioid receptors. With antipruritic ...

LY 106737
(CAS: 82970-72-7)

LY 106737 is phenylpiperidine opioid receptor antagonist, but no detailed information has been published yet.

LY2795050
(CAS: 1346133-08-1)

LY2795050, a κ-opioid Receptor antagonist, has been found to be effective in imaging KOR behaving as a PET tracer. IC50: 0.72 nM and 25.8 nM for κ-opioid Recept...

Naloxegol
(CAS: 854601-70-0)

Naloxegol is a CYP3A4 enzyme inhibitor. It is also a peripherally-selective opioid antagonist. It is used as the treatment of opioid-induced constipation. lt is...

CAS 141801-26-5 Endomorphin 2

Endomorphin 2
(CAS: 141801-26-5)

Endomorphin 2, an andogenous peptide, has high affinity and specificity for the μ-opioid receptor and displays reasonable affinities for kappa3 binding sites, w...

Difelikefalin
(CAS: 1024828-77-0)

Difelikefalin is an analgesic opioid peptide acting as a peripherally specific, highly selective agonist of the κ-opioid receptor (KOR). It acts as an analgesic...

CAS 34140-59-5 Trimebutine Maleate

Trimebutine Maleate
(CAS: 34140-59-5)

Trimebutine is an opioid receptor agonist used as spasmolytic agent abdominal pain.

BAN ORL 24
(CAS: 1401463-54-4)

BAN ORL 24, a spiro-isobenzofuran compound, has been found to be a NOP receptor antagonist and could be used to restrain the reduction of locomotor motions with...

Chemical Structure

CAS 156053-89-3 Alvimopan

Quick Inquiry

Verification code

Featured Items